CYC 116

Drug Profile

CYC 116

Alternative Names: CYC-116

Latest Information Update: 21 Apr 2016

Price : $50

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 16 Apr 2008 Preclinical pharmacodynamics data in Haematological malignancies presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,
  • 27 Nov 2007 Interim efficacy and safety data from a phase I trial in solid tumours released by Cyclacel
  • 30 Jun 2007 Phase-I clinical trials in Solid tumours in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top